13th World Pharma Market and Drug Pricing Congress

Pharma Market 2019

Theme: Future of Drug Costs, Drug Pricing and Pharmacoeconomics

13th World Pharma Market and Drug Pricing Congress will be held during November 18-19, 2019 at Tokyo, Japan. The main theme of the conference is ''Future of Drug Costs, Drug Pricing and Pharmacoeconomics''. Annual Pharma Pricing and Marketing Congress, which is your single best opportunity to reach the largest assemblage of participants from the pharmacology community. Annual Pharma Pricing and Market Congress gives you excellent opportunities to hear from payers, pharma, patient led organizations and providers discuss pricing, patient centricity and global market access all in one place. With collaboration high on the agenda, Attend most respected market access and pricing conference to benchmark your strategic decision making. Annual Pharma Pricing and Marketing Congress, which is your single best opportunity to reach the largest assemblage of participants from the pharmacology community. Pharma Pricing and Market Congress gives you excellent opportunities to hear from payers, pharma, patient led organizations and providers discuss pricing, patient centricity and global market access all in one place. With collaboration high on the agenda, Attend most respected market access and pricing conference to benchmark your strategic decision making.

Session 1: Pharma Marketing

Pharmaceutical company is a commercial business licensed to research, develop, market and or distribute drugs, most commonly in the context of healthcare. The most influencing factors are raising costs of the medicines, growing risks, changing consumer needs and tightening regulations. Pharma Industries represented a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 bn by 2018.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 2: Generic Medicines

Generic drug is the drug which is marketed without any brand name and they are basically less expensive and cost effective than the most of the branded drug. Generics drugs are cost effective alternatives from the branded drugs. Generics are similar to branded drugs in terms of purity, efficacy and are perceived to be safer as compared to new drug molecules, as they tend to be older and time tested. Pharmaceutical market of generic drugs is increasing day by day. The present communication describes various aspects and prospects of generic drugs in the world.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 3: Pharma Digitization

Digitalisation is fundamentally changing the healthcare industry. The Pharma industry, as a core part of healthcare, is no exception to this. New technologies and innovations are already enabling pharma companies to improve medicine development and patient care. At the same time, healthcare payers and other customers of pharma companies are demanding more and better data on the medication efficacy and improved patient quality of life. These demands cannot be fulfilled by purely traditional means.

One might say that Pharma business is undergoing a perfect storm : a concurrent transformation on multiple, unrelated areas changing the whole product lifecycle from early drug development to manufacturing and patient care. This transformation will not only challenge the incumbents but also create opportunities for new entrants outside of pharma business whose innovation and business clock speed are on a completely different level.

It is obvious that these market challenges and requirements can’t be met with the current products, business models and operations. Therefore the pharma business transformation is inevitable which will lead to the digitalisation of the pharma products, business models, operations and ultimately – the patient care. Enter the era of Pharma Digitalisation

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 4: Health Economics and Outcomes Research (HEOR)

In order to gain market access and remain competitive, pharmaceutical and medical technology manufacturers must be able to demonstrate clinical and economic evidence to providers, healthcare decision-makers and payers. Now more than ever, pricing pressure and regulatory restrictions are generating increased demand for this kind of outcomes evidence. In an increasingly complicated legislative environment, the methods used to gain market access have to change. Payers, physicians and patients each have their own particular interest in a product. As a scientific discipline that quantifies the economic and clinical outcomes of medical technology, HEOR helps manufacturers of pharmaceuticals and devices communicate the value of their innovations to stakeholders. It is becoming a central component for demonstrating product value, encompassing aspects such as clinical efficacy, real-world data, patient quality of life reports, opportunity cost of various treatment mixes, budget impact, and cost-effectiveness models. All of which eventually supports the allocation of resources for the listing, pricing and reimbursement of new products.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 5: Health Technology Assessment HTA

The International Network of Agencies for Health Technology Assessment defines HTA as “The systematic evaluation of properties, effects, and  impacts of health care technology. It may address the direct, intended consequences of technologies as well as their indirect, unintended.

Its main purpose is to inform technology-related policymaking in health care. HTA is conducted by interdisciplinary groups using explicit analytical frameworks drawing from a variety of methods. HTA in relation to pharmaceuticals encompasses evaluations relevant to price setting or pricing policies.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 6: Regulatory Reimbursement

Pharmaceutical Industry regulation is the statute itself, the Federal Food, Drug and Cosmetic Act of 1938, as amended by the Drug Amendments of 1962. The statute establishes a structure; that is, it establishes the most stringent form of regulation, pre-marketing approval, from among a wide variety of regulatory mechanisms (such as pre-marketing notification, pre-marketing testing, or standard-marketing) that could have been selected. Although the statute mandates the general structure of the regulatory system, the Food and Drug Administration (FDA) is given wide latitude to do, in effect, anything it wants within that extraordinarily broad concept of pre-market approval. All daily administrative practice and procedure at the FDA (e.g., deciding whether a manufacturer needs to perform another study or whether to approve a product for marketing now or 10 years from now) is within the agency's discretion.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 7: Pharmaceutical Supply and Distribution Chain

An overall pharmaceutical pricing strategy, countries should consider regulating distribution chain mark-ups. As part of an overall pharmaceutical pricing strategy, countries should consider regulating retail chain mark-ups. If mark-ups are regulated, countries should consider using regressive mark-ups lower mark-up for higher-priced products rather than fixed percentage markups, given the incentive that the latter provides for higher-priced products to receive a higher net margin.

Countries should consider using remuneration regulation to provide incentives for supplying specific medicines (generics, low volume medicines, reimbursable medicines) or to protect specific patients or population groups. In systems where rebates and discounts in the distribution chain occur countries should consider regulating them and should make them transparent. The information should be taken into account when reviewing and regulating markups and prices.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 8: Pharmaceutical Auditing

Pharmaceuticals must be produced consistently and must be strictly controlled to meet both national and international standards appropriate for their intended use. Strict regulatory requirements must be met including those specified by US Food and Drug Administration (FDA) or UK Medicines and Healthcare Products Regulatory Authority (MHRA).

Pharmaceutical auditing offer Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) audit services helping our clients to ensure that all relevant regulatory requirements (FDA, NF, MHRA) are met. We provide auditing solutions including pharmaceutical shared audits for all types of pharmaceutical products such as active pharmaceutical ingredients (APIs), drug products, excipients, over-the-counter products, vaccines and vitamins.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 9: Market Access

Market access is the process of ensuring that patients who can benefit from a particular drug have easy and consistent access to that at the right price. Requirement for market access is evidence of clinical effectiveness and cost effectiveness of the product. Market access is no longer about simply gaining marketing authorization for the product.

Market access includes pricing, reimbursement, Health Technology Assessment (HTA) authority recommendations and formulary references on a local and national level. Value based pricing is now a key consideration when marketing a product. This means that the price should reflect the value of the drug.

The right market access strategy can help pharmaceutical companies set their products apart and perhaps realize a preferred position on payer formularies at desired prices and reimbursement levels. Pharmaceutical companies that want to build a smart and robust market access strategy are now beginning to see the value of partnering with service providers with deep domain knowledge, experience in a variety of therapeutic areas and regulatory environments, and an understanding of highly complex and dynamic healthcare systems.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Session 10: Market Intelligence (MI)

Most important things to drive in strategy and success in the marketplace is the role of market intelligence. Samples a broad cross section of firms regarding their level of MI activity; MI data sources and MI accountability. Regarding MI activity and its value to consumer intelligence, two thirds of the companies indicated a dramatic increase in level of activity and nearly 54 per cent said the impact of MI contributes heavily to tactical and strategic decision making. One third said activity was level, while none indicated a reduction. 44 per cent indicated MI contributed somewhat to decision making and only 2 per cent felt MI contributed little to strategy and success in the marketplace. Regarding MI data sources, customers, manufacturing, and R&D are the central source. Regarding MI accountability, about half held marketing accountable for MI.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Special Session: Pharmaceutical Science

We are introducing a special session on Pharmaceutical Science in Pharma Market 2018 conference to create a great opportunity for Academicians, Scientists, Clinicians, Researcher,  Pharmaceutical Organizations, Clinical Research Organizations and all representatives of Pharmaceutical to meet our business experts in Annual Pharma Pricing & Marketing Congress.

Pharmaceutical sciences combine a broad range of scientific disciplines concerned with Clinical Research, Drug Discovery, Drug Design, Drug Delivery, Drug Action, Drug Analysis, Pharmacoeconomics, and Regulatory Affairs. Pharmaceutical sciences are further subdivided into several specialties they are Pharmacology, Pharmacodynamics, Pharmacokinetics, Pharmaceutical Toxicology, Pharmacogenomics, Pharmaceutical chemistry, Pharmaceutics, Pharmacognosy.

Pharma Conference | Pharma Marketing Conference | Marketing Workshop | Pharma Marketing Meeting | Pharmaceutical Conference | Pharmaceutical Symposium | Medical Conference | Pharmaceutical Forum | Annual Pharma Pricing & Marketing Congress | Pharmacological   Event

Scope and Importance:

Medicines account for 20–60% of health spending in low- and middle-income countries, compared with 18% in countries of the Organisation for Economic Co-operation and Development. Up to 90% of the population in developing countries purchase medicines through out-of-pocket payments, making medicines the largest family expenditure item after food. As a result, medicines, particularly those with higher costs, may be unaffordable for large sections of the global population and are a major burden on government budgets. The Millennium Development Goals include the target: “In cooperation with pharmaceutical companies, provide access to affordable, essential drugs in developing countries.” Initiatives to stimulate availability and access through manufacturing innovations, procurement mechanisms, or supply chain improvements require management of pricing to have sustainable impact. The past ten years have seen the introduction of several initiatives at both global and regional levels to support countries in managing pharmaceutical prices. Despite some clear successes, many countries are still failing to implement the policy and programme changes needed to improve access to affordable medicines. This guideline was developed to assist national policy-makers and other stakeholders in identifying and implementing policies to manage pharmaceutical prices. Although the feasibility of these policies in countries of all income levels was considered, special consideration was given to implementation needs in low- and middle-income countries, where the pharmaceutical sector may be less regulated. References to low- and middle income countries are therefore intended to highlight specific implementation needs and do not to exclude the appropriateness for high-income settings.

Market Value:

Overview of the global pharmaceutical market by tracking 13 market segments of that industry in four geographic regions. Thus, a total of 52 segments of the global pharmaceutical industry are tracked. The Pharmaceutical Industries manufacturers of bone, respiratory, immunology, dermatology, cardiovascular, diabetes, obesity, urinary kidney diseases, gastrointestinal, neurosciences, infectious diseases, ophthalmology, oncology, women’s health endocrine, vaccines, consumer health OTC, and others providing a five-year (2007-2012) annual trend analysis that highlights market size, profit and cost structure for North America, Europe,and all other countries. And  addressing market opportunities for next five years (2013- 2018) for each of these regions.

North America is projected to lead the pharmaceutical market. Vaccine industry is expected to record the highest growth during the forecast period. ROW industry is expected to witness the highest growth during 2013-2018. Government initiatives in Brazil to encourage drugs industries by providing free pricing policies and special financial investment options will attract the industry players. APAC holds good growth  potential for the future.

This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global pharmaceutical industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.

                                                    

                                                   Fig: Expenditure by Type of Pharmaceutical Marketing (2017)

Major Pharmaceutical Associations around the Globe:

  • American Association of Pharmaceutical Scientists (AAPS)
  • International Pharmaceutical Federation (FIP)
  • International Pharmaceutical Students' Federation (IPSF)
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Generics and Biosimilar Medicines Association (EGA)
  • Canadian Generic Pharmaceutical Association (CGPA)
  • Generic Pharmaceutical Association (GPhA)
  • ORPHANET Parenteral Drug Association
  • Association of the British Pharmaceutical Industry (ABPI)

Top universities in UAE:

  • Gulf Medical University.
  • University of Sharjah.
  • Dubai Pharmacy College.
  • Ajman University.
  • Ras al-Khaimah Medical and Health Sciences University.
  • Al Ain University of Science and Technology.

Future Prospect:

Pharmaceutical market size estimates in terms of (US $) value by regions and by segments.Global pharmaceutical market annual  trend (2007-2012) and forecast (2013-2018) new product launch, merger and acquisition activity in global pharmaceutical market.Gross and net profit trends in the global pharmaceutical industry.Cost structure trend in the global as well as regional pharmaceutical industry.More than 58 valuable figures/charts and five tables are provided in this report.

Conclusion:
Pharmaceutical Industry is considered the most knowledge based industry in the world.What may seen a small discovery in pharmaceutical technology could lead to unprecedented change in the world. Even through companies make massive investment in R&D, they still requires years even decades to develop a usefull product. According to one acticle the process of drug discovery is elaborate required on an average 8-10 years at a cost of US$300 million to reach a new drug to the market.

Reference:

https://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

https://www.statista.com/topics/1764/global-pharmaceutical-industry

http://www.eulerhermes.com/economic-research/sector-risks/Global-Pharmaceuticals-Report/Pages/default.aspx

  • Pharma Marketing
  • Generic Medicines
  • Pharma Digitization
  • Health Economics and Outcomes Research
  • Health Technology Assessment
  • Regulatory Reimbursement
  • Pharmaceutical Supply and Distribution Chain
  • Pharmaceutical Auditing
  • Market Intelligence
  • Market Access